摘要
生物型人工肝在严重广泛肝细胞功能受损特别是急性肝衰竭的临床应用方面获得了一致认可,而肝细胞的获取是生物型人工肝的根本所在,无论是何种来源的肝细胞,获取后其功能正常高效发挥是所有工作的导向。因此,获取良好状态的人工肝种子细胞是一切工作的前提。由于分化、培养和增殖等方面的限制,获取人工肝种子细胞的常规途径并不能满足临床对种子细胞的需求。2006年日本学者通过重编程体细胞成功诱导成具有多分化潜能的iPS细胞,这为生物型人工肝在获取安全有效种子细胞来源方面带来了新的曙光,本文主要论述iPS细胞的来源、分化及其特性,以及将其应用于临床特别是生物型人工肝所面临的主要问题,并对其前景进行探讨。
Bioartificial liver support system has been wildly used in severe liver damage diseases especially in acute hepatic failure.High-performance hepatocyte is the basic part for bioartificial liver support system.But conventional methods of getting functional hepatic cells can＇t meet clinical demand due to the difficulties of cell differentiation,cultivation and proliferation.Professor Yamanaka and his group found induced pluripotent stem（iPS） cell by cell reprogramming.This gives us a new hope for bioartificial liver support system cell source.Our article focuses on the origin of iPS cell,its differentiation,other characteristics,the problems and future it will face in clinical trial especially in bioartificial liver support system.
出处
《胃肠病学和肝病学杂志》
CAS
2010年第3期193-195,共3页
Chinese Journal of Gastroenterology and Hepatology
关键词
生物型人工肝
肝细胞
诱导性多潜能干细胞
Bioartificial liver support system Hepatocyte Induced pluripotent stem cell
